Parametric Portfolio Associates LLC raised its stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 2.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 22,966 shares of the medical research company’s stock after purchasing an additional 492 shares during the period. Parametric Portfolio Associates LLC’s holdings in Accelerate Diagnostics were worth $628,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its holdings in Accelerate Diagnostics by 7.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 117,236 shares of the medical research company’s stock valued at $3,207,000 after purchasing an additional 7,930 shares during the period. Wells Fargo & Company MN grew its holdings in Accelerate Diagnostics by 21.2% during the second quarter. Wells Fargo & Company MN now owns 73,328 shares of the medical research company’s stock valued at $2,005,000 after purchasing an additional 12,840 shares during the period. Bank of America Corp DE grew its holdings in Accelerate Diagnostics by 51.0% during the first quarter. Bank of America Corp DE now owns 15,200 shares of the medical research company’s stock valued at $368,000 after purchasing an additional 5,132 shares during the period. Oaktop Capital Management II L.P. bought a new stake in Accelerate Diagnostics during the second quarter valued at about $4,239,000. Finally, Marshall Wace North America L.P. bought a new stake in Accelerate Diagnostics during the second quarter valued at about $1,213,000. 45.43% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Parametric Portfolio Associates LLC Boosts Position in Accelerate Diagnostics, Inc. (AXDX)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2017/11/23/parametric-portfolio-associates-llc-boosts-position-in-accelerate-diagnostics-inc-axdx.html.

In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 276,200 shares of the company’s stock in a transaction dated Thursday, October 12th. The stock was purchased at an average price of $19.74 per share, with a total value of $5,452,188.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack W. Schuler acquired 51,600 shares of the company’s stock in a transaction dated Wednesday, October 11th. The stock was acquired at an average cost of $20.27 per share, with a total value of $1,045,932.00. The disclosure for this purchase can be found here. Insiders have acquired 981,667 shares of company stock valued at $18,879,924 in the last three months. 50.00% of the stock is currently owned by corporate insiders.

Shares of Accelerate Diagnostics, Inc. (AXDX) opened at $26.30 on Thursday. Accelerate Diagnostics, Inc. has a fifty-two week low of $16.75 and a fifty-two week high of $30.45.

Several analysts have issued reports on AXDX shares. BidaskClub lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Finally, ValuEngine lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Three analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $33.00.

Accelerate Diagnostics Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.